In addition, FXR activation has been demonstrated to inhibit the expression of monocyte chemoattractant protein 1 (MCP-1, also called as CCL-2) [86], which is an important chemokine involved in the progression of NASH [87]. Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.